Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the approval of Leqembi (lecanemab) for mild cognitive impairment due to ...
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment. Eisai Co., Ltd. and Biogen Inc. announced that the U.S. FDA ...
6don MSN
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
Eisai reported strong Q3 2024 performance driven by its leading products, particularly LEQEMBI, which saw robust sales growth across key regions. Management expressed confidence in achieving its ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback